Solifenacin Succinate 5mg or 10mg Once Daily in the Treatment of Urgency Symptoms

PHASE3CompletedINTERVENTIONAL
Enrollment

973

Participants

Timeline

Start Date

April 30, 2004

Primary Completion Date

October 31, 2005

Study Completion Date

October 31, 2005

Conditions
Urinary Bladder, Overactive
Interventions
DRUG

Solifenacin succinate

oral

DRUG

Placebo

oral

Trial Locations (78)

Unknown

Antwerp

Bruges

Brussels

Ghent

Hasselt

Kortrijk

Leuven

Liège

Ostrava

Prague

Zlín

Al Mansurah

Lille

Lomme

Mulhouse

Nantes

Nîmes

Paris

Aichach

Bad Neuenaher

Bamberg

Bautzen

Berlin

Dierdorf

Dülmen

Düsseldorf

Frankfurt

Henningsdorf

Munich

Neustadt

Nuremberg

Planegg

Athens

Crete

Ioannina

Budapest

Nyíregyháza

Pécs

Szeged

Tatabánya

Bari

Catanzaro

Cinisello Balsamo

Magenta

Modena

Perugia

Turin

Udine

Bydgoszcz

Wroclaw

Abrantes

Lisbon

Porto

Santarém

Moscow

Banska Bysterica

Martin

Žilina

Barcelona

Coaña

Córdoba

Madrid

Mérida

San Cristóbal de La Laguna

Seville

Birmingham

Cottingham

Croydon

Edinburgh

Huntingdon

London

Manchester

Oldham

Stoke-on-Trent

Sunderland

Torbay

Welwyn Garden City

Worthing

Sponsors
All Listed Sponsors
lead

Astellas Pharma Inc

INDUSTRY

NCT00801944 - Solifenacin Succinate 5mg or 10mg Once Daily in the Treatment of Urgency Symptoms | Biotech Hunter | Biotech Hunter